Bank of New York Mellon Corp increased its stake in Savara Inc (NASDAQ:SVRA) by 3.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 82,940 shares of the company’s stock after purchasing an additional 2,830 shares during the quarter. Bank of New York Mellon Corp’s holdings in Savara were worth $628,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in SVRA. Simplex Trading LLC boosted its stake in Savara by 246.1% in the 4th quarter. Simplex Trading LLC now owns 4,997 shares of the company’s stock worth $37,000 after purchasing an additional 3,553 shares during the period. Virtu Financial LLC acquired a new position in Savara in the 4th quarter worth $82,000. MetLife Investment Advisors LLC boosted its stake in Savara by 55.2% in the 3rd quarter. MetLife Investment Advisors LLC now owns 20,243 shares of the company’s stock worth $226,000 after purchasing an additional 7,196 shares during the period. Rhumbline Advisers boosted its stake in Savara by 54.7% in the 4th quarter. Rhumbline Advisers now owns 37,090 shares of the company’s stock worth $281,000 after purchasing an additional 13,120 shares during the period. Finally, Virtus ETF Advisers LLC acquired a new position in Savara in the 4th quarter worth $305,000. 47.86% of the stock is owned by hedge funds and other institutional investors.
Shares of NASDAQ:SVRA opened at $10.85 on Friday. The company has a current ratio of 15.63, a quick ratio of 15.63 and a debt-to-equity ratio of 0.23. Savara Inc has a one year low of $6.21 and a one year high of $14.06. The stock has a market cap of $392.34 million, a price-to-earnings ratio of -8.41 and a beta of 1.06.
A number of equities analysts recently weighed in on the stock. Zacks Investment Research raised shares of Savara from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a research note on Thursday, April 11th. ValuEngine raised shares of Savara from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. BidaskClub raised shares of Savara from a “hold” rating to a “buy” rating in a research report on Friday, April 5th. LADENBURG THALM/SH SH reissued a “buy” rating and set a $21.00 price target on shares of Savara in a research report on Monday, April 1st. Finally, Canaccord Genuity set a $22.00 price target on shares of Savara and gave the stock a “buy” rating in a research report on Monday, March 25th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $21.17.
In other Savara news, COO Jaakko Taneli Jouhikainen sold 7,815 shares of the business’s stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $9.00, for a total transaction of $70,335.00. Following the sale, the chief operating officer now directly owns 184,754 shares of the company’s stock, valued at approximately $1,662,786. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO David L. Lowrance sold 7,500 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $9.02, for a total transaction of $67,650.00. Following the sale, the chief financial officer now directly owns 2,446 shares in the company, valued at $22,062.92. The disclosure for this sale can be found here. Insiders have sold a total of 42,761 shares of company stock worth $385,749 over the last three months. Insiders own 6.10% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Savara Inc (SVRA) Shares Bought by Bank of New York Mellon Corp” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4325987/savara-inc-svra-shares-bought-by-bank-of-new-york-mellon-corp.html.
Savara Company Profile
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
Further Reading: Price to Earnings Ratio (PE) Basics
Want to see what other hedge funds are holding SVRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Savara Inc (NASDAQ:SVRA).
Receive News & Ratings for Savara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Savara and related companies with MarketBeat.com's FREE daily email newsletter.